Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (7): 566-570.doi: 10.35541/cjd.20210726
• Original Articles • Previous Articles Next Articles
Wang Qian1, Qi Bo2, Zhang Lixia1, Liu Wei1, Lan Yunping3
Received:
2021-10-08
Revised:
2021-12-31
Online:
2022-07-15
Published:
2022-07-05
Contact:
Qi Bo; Lan Yunping
E-mail:674660470@qq.com; lanyunping929@163.com
Wang Qian, Qi Bo, Zhang Lixia, Liu Wei, Lan Yunping. Comparison of the performance of SCORTEN and ABCD-10 in evaluating the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. Chinese Journal of Dermatology, 2022, 55(7): 566-570.doi:10.35541/cjd.20210726
[1] | Bastuji⁃Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity⁃of⁃illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000,115(2):149⁃153. doi: 10.1046/j.1523⁃1747.2000.00061.x. |
[2] | Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center[J]. J Burn Care Res, 2008,29(1):141⁃146. doi: 10.1097/BCR.0b013e31815f3865. |
[3] | Wambier CG, Hoekstra TA, Wambier S, et al. Epidermal necrolysis: SCORTEN performance in AIDS and non⁃AIDS patients[J]. An Bras Dermatol, 2019,94(1):17⁃23. doi: 10.1590/abd1806⁃4841.20196864. |
[4] | 王昱璐, 左亚刚, 刘洁, 等. SCORTEN评分对中毒性表皮坏死松解症和Stevens⁃Johnson综合征评估分析[J]. 中华皮肤科杂志, 2016,49(9):651⁃653. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.09.011. |
[5] | 中华医学会皮肤性病学分会药物不良反应研究中心. Stevens⁃Johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志, 2021,54(5):376⁃381. doi: 10.35541/cjd.2020 1177. |
[6] | Zavala S, O′Mahony M, Mahony M, et al. How does SCORTEN score?[J]. J Burn Care Res, 2018,39(4):555⁃561. doi: 10.1093/jbcr/irx016. |
[7] | Torres⁃Navarro I, Briz⁃Redón Á, Botella⁃Estrada R. Accuracy of SCORTEN to predict the prognosis of Stevens⁃Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta⁃analysis[J]. J Eur Acad Dermatol Venereol, 2020,34(9):2066⁃2077. doi: 10.1111/jdv.16137. |
[8] | Zhang AJ, Nygaard RM, Endorf FW, et al. Stevens⁃Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10⁃year experience[J]. Int J Dermatol, 2019,58(9):1069⁃1077. doi: 10.1111/ijd.14409. |
[9] | Noe MH, Rosenbach M, Hubbard RA,et al. Development and validation of a risk prediction model for in⁃hospital mortality among patients with Stevens⁃Johnson syndrome/toxic epidermal necrolysis⁃ABCD⁃10[J]. JAMA Dermatol, 2019,155(4):448⁃454. doi: 10.1001/jamadermatol.2018.5605. |
[10] | Bastuji⁃Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens⁃Johnson syndrome, and erythema multiforme[J]. Arch Dermatol, 1993,129(1):92⁃96. |
[11] | Deng Q, Fang X, Zeng Q, et al. Severe cutaneous adverse drug reactions of Chinese inpatients: a meta⁃analysis[J]. An Bras Dermatol, 2017,92(3):345⁃349. doi: 10.1590/abd1806⁃4841. 20175171. |
[12] | Carrasquillo OY, Santiago⁃Vazquez M, Cardona R, et al. Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study[J]. Int J Dermatol, 2019,58(11):1293⁃1299. doi: 10.1111/ijd.14493. |
[13] | Yang L, Shou YH, Li F, et al. Retrospective study of 213 cases of Stevens⁃Johnson syndrome and toxic epidermal necrolysis from China[J]. Burns, 2020,46(4):959⁃969. doi: 10.1016/j.burns. 2019.10.008. |
[14] | Watanabe T, Go H, Saigusa Y, et al. Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients[J]. Allergol Int, 2021,70(2):229⁃234. doi: 10.1016/j.alit.2020.11.004. |
[15] | Hu CH, Chang NJ, Liu EK, et al. SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population[J]. J Eur Acad Dermatol Venereol, 2013,27(5):628⁃633. doi: 10.1111/j.1468⁃3083.2012.04502.x. |
[16] | Yang MS, Lee JY, Kim J, et al. Incidence of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a nationwide population⁃based study using national health insurance database in Korea[J/OL]. PLoS One, 2016,11(11):e0165933. doi: 10. 1371/journal.pone.0165933. |
[17] | Tuchinda P, Chularojanamontri L, Sukakul T, et al. Cutaneous adverse drug reactions in the elderly: a retrospective analysis in Thailand[J]. Drugs Aging, 2014,31(11):815⁃824. doi: 10.1007/s40266⁃014⁃0209⁃x. |
[18] | Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens⁃Johnson syndrome and toxic epidermal necrolysis in the UK[J]. J Invest Dermatol, 2017,137(6):1240⁃1247. doi: 10.1016/j.jid.2017.01.031. |
[19] | Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and mortality of Stevens⁃Johnson syndrome and toxic epidermal necrolysis in United States adults[J]. J Invest Dermatol, 2016,136(7):1387⁃1397. doi: 10.1016/j.jid.2016.03.023. |
[20] | Bettuzzi T, Penso L, de Prost N, et al. Trends in mortality rates for Stevens⁃Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017[J]. Br J Dermatol, 2020,182(1):247⁃248. doi: 10.1111/bjd. 18360. |
[21] | Koh HK, Fook⁃Chong S, Lee HY. Assessment and comparison of performance of ABCD⁃10 and SCORTEN in prognostication of epidermal necrolysis[J]. JAMA Dermatol, 2020,156(12):1294⁃1299. doi: 10.1001/jamadermatol.2020.3654. |
[22] | Shou Y, Yang L, Yang Y, et al. Cohort study of patients with Stevens⁃Johnson syndrome and toxic epidermal necrolysis in China: evaluation of risk models and new predictor of pulmonary consolidation on computed tomography[J]. Front Med, 2021,15(4):585⁃593. doi: 10.1007/s11684⁃020⁃0817⁃2. |
[23] | Duplisea MJ, Roberson ML, Chrisco L, et al. Performance of ABCD⁃10 and SCORTEN mortality prediction models in a cohort of patients with Stevens⁃Johnson syndrome/toxic epidermal necrolysis[J]. J Am Acad Dermatol, 2021,85(4):873⁃877. doi: 10.1016/j.jaad.2021.04.082. |
[1] | Shih Yanting, Li Hao, Zheng Jie, Cao Hua. Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies [J]. Chinese Journal of Dermatology, 2022, 55(7): 633-636. |
[2] | Huang Yaxin, He Yuanmin, Huang Shuli, Xiong Xia, Deng Yongqiong. An investigation into clinical significance of serum chitinase 3-like protein 1 in pemphigus vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(6): 523-527. |
[3] | Zhang Xiao, Chen Fengming, Liu Lin, Luo Li, Guo Jin, Gao Tianwen, Shi Qiong. Analysis of clinicopathological features and prognosis of 163 cases of stage Ⅰ cutaneous melanoma [J]. Chinese Journal of Dermatology, 2022, 55(5): 389-394. |
[4] | Shen Chen, Tao Juan. Evolution of assessment of long-term control of and treat-to-target in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(5): 442-445. |
[5] | Fu Chao, Wu Jiaona, Lang Wenchao, Gao Fei, Niu Guiye, Bian Peiwen, Gao Minhong, Si Xiaoqing, Xin Linlin. Role of dermoscopy in assessing vitiligo activity [J]. Chinese Journal of Dermatology, 2022, 55(3): 268-271. |
[6] | Li Hao, Wang Li, Han Xianwei, Sun Tong, Su Fang, Sun Xiaodong, Han Ying, Yang Guoling, Liu Xiaoming, Wang Kaibo. Analysis of clinical characteristics of bullous pemphigoid developing after the treatment with dipeptidyl peptidase-Ⅳ inhibitors in 32 patients with diabetes mellitus [J]. Chinese Journal of Dermatology, 2022, 55(3): 213-218. |
[7] | Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279. |
[8] | Jiao Xiaoyan, Yin Guangwen, Yin Yakun, Li Dongqin. Clinical analysis of 25 cases of herpes zoster during pregnancy or the perinatal period [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210384-e20210384. |
[9] | Lin Yuchieh, Liu Fengjie, Gao Yumei, Liu Xiangjun, Xu Bufang, Li Yingyi, Lai Pan, Chen Zhuojing, Sun Jingru, Tu Ping, Wang Yang. Significance of lysophosphatidic acid receptor 6 in the large-cell transformation of mycosis fungoides and its effect on the proliferation and apoptosis of cutaneous T-cell lymphoma cells [J]. Chinese Journal of Dermatology, 2022, 55(2): 102-109. |
[10] | Ma Xiao, Li Chengrang, Wang Baoxi, He Yanyan, Xu Haoxiang. Severity assessment criteria for acne inversa/hidradenitis suppurativa [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210236-e20210236. |
[11] | Zou Meirong, Wang Sheng. Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2022, 0(1): 20201221-e20201221. |
[12] | Long Hai, Jiang Li, Qiu Yueqi, Yao Nan, Liu Licong, Xie Yuming, Xiong Feng, Tan Siqi, Kuang Qiqi, You Ruixuan, Chai Ke, Luo Xin, Long Haojun, Xin Yue, Guo Ziyu, Wang Jiaqi, Tan Yixin, Zhang Qing, Zhang Guiying, Li Yaping, Su Yuwen, Xiao Rong, Lu Qianjin, . Clinical analysis of 1 057 patients with critical illnesses in a dermatological ward [J]. Chinese Journal of Dermatology, 2021, 54(9): 790-797. |
[13] | Yu Yingyuan, Li Ying, Yu Zengyang, Zheng Jianfeng, Zhang Xilin, Ding Yangfeng, Shi Yuling, . Efficacy and safety of infliximab in the treatment of severe plaque psoriasis and its effect on the expression of programmed cell death-1 and programmed cell death ligand-1 [J]. Chinese Journal of Dermatology, 2021, 54(7): 590-596. |
[14] | Adverse Drug Reaction Research Center of Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2021, 54(5): 376-381. |
[15] | Gao Meiyan, Zhao Jianhong, Zhao Tao, Li Bing, Tian Pei, Wang Guan, Ma Cuiling, Gao Tianwen, Guo Weinan. Clinicopathological characteristics and prognosis of 87 cases of trauma-related melanomas [J]. Chinese Journal of Dermatology, 2021, 54(4): 289-293. |
|